| Business Summary | | Titan
Pharmaceuticals,
Inc.
is
a
biopharmaceutical
company
developing
proprietary
therapeutics
for
the
treatment
of
central
nervous
system
disorders,
cancer
and
other
serious
and
life-threatening
diseases.
The
Company's
product
development
programs
focus
on
large
pharmaceutical
markets
with
significant
unmet
medical
needs
and
commercial
potential.
The
Company
has
nine
products
in
development,
seven
of
which
are
in
clinical
development,
with
two
products
in
expanded
human
trials
for
safety
and
efficacy,
known
as
Phase
III
clinical
trials.
The
Company
has
five
products
in
trials
for
preliminary
efficacy
and
dosing,
and
in
trials
for
initial
human
safety
and
evidence
of
efficacy,
known
as
Phase
II
and
Phase
I/II
clinical
trials,
respectively.
In
addition
to
these
programs,
the
Company
has
two
products
in
preclinical
development.
Some
of
the
Company's
preclinical
product
development
is
conducted
through
its
two
consolidated
subsidiaries,
Ingenex,
Inc.
and
ProNeura,
Inc. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Titan
Pharmaceuticals
develops
proprietary
therapeutics
for
the
treatment
of
central
nervous
system
disorders,
cancer
and
other
serious
and
life-threatening
diseases.
For
the
six
months
ended
6/30/01,
revenues
totalled
$3.5
million,
up
from
$616
thousand.
Net
loss
rose
5%
to
$6.4
million.
Revenues
reflect
the
license
fee
payment
from
Novartis
Pharma
AG
for
the
development
of
iloperidone
in
Japan.
Higher
loss
reflects
increased
research
and
development
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Louis Bucalo, M.D., 42 Chairman,
Pres, CEO | $262K | Robert Farrell, 51 CFO,
Exec. VP | 195K | Sunil Bhonsle, 51 COO,
Exec. VP | 203K | Victor Bauer, Ph.D., 65 Exec.
Director of Corp. Devel., Director | -- | Richard Allen, Ph.D., 58 Exec.
VP, Cell Therapy | 203K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|